Annual EBITDA
-$85.84 M
+$36.67 M+29.93%
March 31, 2024
Summary
- As of February 22, 2025, PRTG annual EBITDA is -$85.84 million, with the most recent change of +$36.67 million (+29.93%) on March 31, 2024.
- During the last 3 years, PRTG annual EBITDA has fallen by -$71.13 million (-483.38%).
- PRTG annual EBITDA is now -169.36% below its all-time high of $123.77 million, reached on March 31, 2018.
Performance
PRTG EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$1.60 M
+$1.24 M+43.50%
September 30, 2024
Summary
- As of February 22, 2025, PRTG quarterly EBITDA is -$1.60 million, with the most recent change of +$1.24 million (+43.50%) on September 30, 2024.
- Over the past year, PRTG quarterly EBITDA has stayed the same.
- PRTG quarterly EBITDA is now -101.29% below its all-time high of $124.77 million, reached on March 31, 2018.
Performance
PRTG Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$78.19 M
+$4.33 M+5.24%
September 30, 2024
Summary
- As of February 22, 2025, PRTG TTM EBITDA is -$78.19 million, with the most recent change of +$4.33 million (+5.24%) on September 30, 2024.
- Over the past year, PRTG TTM EBITDA has stayed the same.
- PRTG TTM EBITDA is now -162.98% below its all-time high of $124.15 million, reached on December 31, 2018.
Performance
PRTG TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PRTG EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.9% | 0.0% | 0.0% |
| 3 y3 years | -483.4% | +60.4% | -429.2% |
| 5 y5 years | -2348.5% | -0.7% | -1301.2% |
PRTG EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -483.4% | +29.9% | at high | +98.5% | -429.2% | +53.8% |
| 5 y | 5-year | -2348.5% | +29.9% | -200.9% | +98.5% | -1583.6% | +53.8% |
| alltime | all time | -169.4% | +29.9% | -101.3% | +98.5% | -163.0% | +53.8% |
Portage Biotech EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.60 M(-43.5%) | -$78.19 M(-5.2%) |
| Jun 2024 | - | -$2.84 M(-88.6%) | -$82.51 M(-2.5%) |
| Mar 2024 | -$85.84 M(-29.9%) | -$24.89 M(-49.0%) | -$84.67 M(-50.0%) |
| Dec 2023 | - | -$48.85 M(+723.8%) | -$169.18 M(+34.7%) |
| Sep 2023 | - | -$5.93 M(+18.7%) | -$125.63 M(+1.9%) |
| Jun 2023 | - | -$5.00 M(-95.4%) | -$123.33 M(+0.7%) |
| Mar 2023 | -$122.51 M(+729.2%) | -$109.41 M(+1963.9%) | -$122.42 M(+617.5%) |
| Dec 2022 | - | -$5.30 M(+46.1%) | -$17.06 M(+7.7%) |
| Sep 2022 | - | -$3.63 M(-11.2%) | -$15.85 M(+1.6%) |
| Jun 2022 | - | -$4.09 M(+1.0%) | -$15.59 M(+5.5%) |
| Mar 2022 | -$14.77 M(+0.4%) | -$4.04 M(-1.1%) | -$14.77 M(-29.2%) |
| Dec 2021 | - | -$4.09 M(+21.2%) | -$20.86 M(+14.7%) |
| Sep 2021 | - | -$3.37 M(+3.2%) | -$18.18 M(+4.2%) |
| Jun 2021 | - | -$3.27 M(-67.7%) | -$17.45 M(+18.6%) |
| Mar 2021 | -$14.71 M(+147.2%) | -$10.13 M(+617.3%) | -$14.71 M(+163.7%) |
| Dec 2020 | - | -$1.41 M(-46.6%) | -$5.58 M(-2.0%) |
| Sep 2020 | - | -$2.64 M(+395.7%) | -$5.69 M(+22.6%) |
| Jun 2020 | - | -$533.00 K(-46.3%) | -$4.64 M(-22.0%) |
| Mar 2020 | -$5.95 M(+69.8%) | -$993.00 K(-34.9%) | -$5.95 M(-24.1%) |
| Dec 2019 | - | -$1.52 M(-4.3%) | -$7.84 M(+19.3%) |
| Sep 2019 | - | -$1.59 M(-13.5%) | -$6.58 M(+27.1%) |
| Jun 2019 | - | -$1.84 M(-36.1%) | -$5.17 M(+47.9%) |
| Mar 2019 | -$3.51 M(-102.8%) | -$2.88 M(+1017.4%) | -$3.50 M(-102.8%) |
| Dec 2018 | - | -$258.00 K(+33.7%) | $124.15 M(+0.1%) |
| Sep 2018 | - | -$193.00 K(+17.7%) | $124.07 M(+0.1%) |
| Jun 2018 | - | -$164.00 K(-100.1%) | $123.93 M(+0.1%) |
| Mar 2018 | $123.77 M(<-9900.0%) | $124.77 M(<-9900.0%) | $123.77 M(-619.7%) |
| Dec 2017 | - | -$343.00 K(+3.0%) | -$23.82 M(-19.4%) |
| Sep 2017 | - | -$333.00 K(+2.5%) | -$29.54 M(-734.9%) |
| Jun 2017 | - | -$325.00 K(-98.6%) | $4.65 M(<-9900.0%) |
| Mar 2017 | -$96.00 K(-99.0%) | -$22.81 M(+275.8%) | -$11.80 K(-100.1%) |
| Dec 2016 | - | -$6.07 M(-117.9%) | $21.01 M(-5.6%) |
| Sep 2016 | - | $33.86 M(-778.6%) | $22.25 M(-269.3%) |
| Jun 2016 | - | -$4.99 M(+178.7%) | -$13.14 M(+43.1%) |
| Mar 2016 | -$9.19 M(+112.6%) | -$1.79 M(-62.9%) | -$9.19 M(+3.9%) |
| Dec 2015 | - | -$4.83 M(+215.3%) | -$8.84 M(+80.6%) |
| Sep 2015 | - | -$1.53 M(+48.3%) | -$4.90 M(+13.3%) |
| Jun 2015 | - | -$1.03 M(-28.4%) | -$4.32 M(+0.0%) |
| Mar 2015 | -$4.32 M(-34.7%) | -$1.44 M(+62.7%) | -$4.32 M(-11.2%) |
| Dec 2014 | - | -$887.00 K(-7.4%) | -$4.86 M(+14.0%) |
| Sep 2014 | - | -$957.70 K(-7.2%) | -$4.27 M(+16.7%) |
| Jun 2014 | - | -$1.03 M(-48.0%) | -$3.66 M(-44.8%) |
| Mar 2014 | -$6.62 M(+359.0%) | -$1.99 M(+582.5%) | -$6.62 M(+29.5%) |
| Dec 2013 | - | -$291.10 K(-16.1%) | -$5.11 M(+13.5%) |
| Sep 2013 | - | -$347.10 K(-91.3%) | -$4.51 M(-26.1%) |
| Jun 2013 | - | -$4.00 M(+733.8%) | -$6.10 M(+399.8%) |
| Mar 2013 | -$1.44 M | -$479.40 K(-251.6%) | -$1.22 M(-5.6%) |
| Dec 2012 | - | $316.30 K(-116.3%) | -$1.29 M(-35.9%) |
| Sep 2012 | - | -$1.94 M(-319.8%) | -$2.02 M(+178.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2012 | - | $882.30 K(-260.0%) | -$724.60 K(-71.1%) |
| Mar 2012 | -$2.47 M(-36.3%) | -$551.30 K(+35.3%) | -$2.51 M(-7.4%) |
| Dec 2011 | - | -$407.60 K(-37.1%) | -$2.71 M(-22.3%) |
| Sep 2011 | - | -$648.00 K(-28.1%) | -$3.49 M(-17.0%) |
| Jun 2011 | - | -$901.00 K(+19.8%) | -$4.20 M(+10.2%) |
| Mar 2011 | -$3.88 M(+18.5%) | -$752.40 K(-36.5%) | -$3.81 M(-20.9%) |
| Dec 2010 | - | -$1.19 M(-13.0%) | -$4.82 M(+13.9%) |
| Sep 2010 | - | -$1.36 M(+166.4%) | -$4.23 M(+18.2%) |
| Jun 2010 | - | -$511.40 K(-70.9%) | -$3.58 M(+10.3%) |
| Mar 2010 | -$3.28 M(+565.1%) | -$1.76 M(+194.6%) | -$3.24 M(+98.5%) |
| Dec 2009 | - | -$596.30 K(-16.4%) | -$1.63 M(+29.4%) |
| Sep 2009 | - | -$713.10 K(+304.7%) | -$1.26 M(+79.9%) |
| Jun 2009 | - | -$176.20 K(+19.1%) | -$702.10 K(+28.8%) |
| Mar 2009 | -$492.60 K(-11.0%) | -$148.00 K(-34.4%) | -$544.90 K(+55.5%) |
| Dec 2008 | - | -$225.60 K(+48.1%) | -$350.50 K(+18.3%) |
| Sep 2008 | - | -$152.30 K(+701.6%) | -$296.30 K(+1.8%) |
| Jun 2008 | - | -$19.00 K(-140.9%) | -$291.20 K(-31.8%) |
| Mar 2008 | -$553.20 K(+1756.4%) | $46.40 K(-127.1%) | -$426.80 K(+3710.7%) |
| Dec 2007 | - | -$171.40 K(+16.4%) | -$11.20 K(-5700.0%) |
| Sep 2007 | - | -$147.20 K(-4.8%) | $200.00(-101.0%) |
| Jun 2007 | - | -$154.60 K(-133.5%) | -$19.80 K(-16.1%) |
| Mar 2007 | -$29.80 K(-95.1%) | $462.00 K(-388.8%) | -$23.60 K(-102.6%) |
| Dec 2006 | - | -$160.00 K(-4.3%) | $917.90 K(+18.6%) |
| Sep 2006 | - | -$167.20 K(+5.6%) | $774.00 K(+96.5%) |
| Jun 2006 | - | -$158.40 K(-111.3%) | $393.80 K(-172.3%) |
| Mar 2006 | -$607.00 K(-84.9%) | $1.40 M(-561.8%) | -$544.50 K(-89.9%) |
| Dec 2005 | - | -$303.90 K(-44.5%) | -$5.40 M(+4.0%) |
| Sep 2005 | - | -$547.40 K(-50.1%) | -$5.19 M(+6.4%) |
| Jun 2005 | - | -$1.10 M(-68.2%) | -$4.88 M(+20.4%) |
| Mar 2005 | -$4.01 M(+274.8%) | -$3.45 M(+3492.8%) | -$4.05 M(+171.5%) |
| Dec 2004 | - | -$96.10 K(-58.9%) | -$1.49 M(+3.3%) |
| Sep 2004 | - | -$233.80 K(-12.9%) | -$1.45 M(+11.3%) |
| Jun 2004 | - | -$268.40 K(-70.0%) | -$1.30 M(+22.8%) |
| Mar 2004 | -$1.07 M(+394.4%) | -$893.80 K(+1724.1%) | -$1.06 M(+431.8%) |
| Dec 2003 | - | -$49.00 K(-43.9%) | -$198.80 K(-14.9%) |
| Sep 2003 | - | -$87.40 K(+223.7%) | -$233.70 K(+17.3%) |
| Jun 2003 | - | -$27.00 K(-23.7%) | -$199.20 K(-8.6%) |
| Mar 2003 | -$216.60 K(-66.5%) | -$35.40 K(-57.8%) | -$217.90 K(-48.7%) |
| Dec 2002 | - | -$83.90 K(+58.6%) | -$425.10 K(-35.2%) |
| Sep 2002 | - | -$52.90 K(+15.8%) | -$656.50 K(+0.8%) |
| Jun 2002 | - | -$45.70 K(-81.2%) | -$651.20 K(+0.5%) |
| Mar 2002 | -$646.20 K(+88.9%) | -$242.60 K(-23.1%) | -$648.10 K(+78.4%) |
| Dec 2001 | - | -$315.30 K(+562.4%) | -$363.20 K(+161.7%) |
| Sep 2001 | - | -$47.60 K(+11.7%) | -$138.80 K(+52.2%) |
| Jun 2001 | - | -$42.60 K(-200.7%) | -$91.20 K(+87.7%) |
| Mar 2001 | -$342.00 K(-63.7%) | $42.30 K(-146.5%) | -$48.60 K(-46.5%) |
| Dec 2000 | - | -$90.90 K | -$90.90 K |
| Mar 2000 | -$942.50 K(+209.7%) | - | - |
| Mar 1999 | -$304.30 K(-19.5%) | - | - |
| Mar 1998 | -$378.10 K | - | - |
FAQ
- What is Portage Biotech annual EBITDA?
- What is the all time high annual EBITDA for Portage Biotech?
- What is Portage Biotech annual EBITDA year-on-year change?
- What is Portage Biotech quarterly EBITDA?
- What is the all time high quarterly EBITDA for Portage Biotech?
- What is Portage Biotech quarterly EBITDA year-on-year change?
- What is Portage Biotech TTM EBITDA?
- What is the all time high TTM EBITDA for Portage Biotech?
- What is Portage Biotech TTM EBITDA year-on-year change?
What is Portage Biotech annual EBITDA?
The current annual EBITDA of PRTG is -$85.84 M
What is the all time high annual EBITDA for Portage Biotech?
Portage Biotech all-time high annual EBITDA is $123.77 M
What is Portage Biotech annual EBITDA year-on-year change?
Over the past year, PRTG annual EBITDA has changed by +$36.67 M (+29.93%)
What is Portage Biotech quarterly EBITDA?
The current quarterly EBITDA of PRTG is -$1.60 M
What is the all time high quarterly EBITDA for Portage Biotech?
Portage Biotech all-time high quarterly EBITDA is $124.77 M
What is Portage Biotech quarterly EBITDA year-on-year change?
Over the past year, PRTG quarterly EBITDA has changed by $0.00 (0.00%)
What is Portage Biotech TTM EBITDA?
The current TTM EBITDA of PRTG is -$78.19 M
What is the all time high TTM EBITDA for Portage Biotech?
Portage Biotech all-time high TTM EBITDA is $124.15 M
What is Portage Biotech TTM EBITDA year-on-year change?
Over the past year, PRTG TTM EBITDA has changed by $0.00 (0.00%)